Merison

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Merison

Property Description
Active ingredient Betahistine (INN)
Form Tablet (oral)
Pharmacological class Antivertigo Agent / Histamine Analogue
General purpose To stabilize inner ear function
Origin Synthetic compound

Merison is a proprietary oral medication containing the active substance Betahistine, and is classified as a specific Antivertigo Agent. The pharmacological profile of Betahistine places it in the class of drugs designed to modulate the histaminergic system. The substance is chemically engineered as a synthetic histamine analogue, a feature which is central to its targeted effect on the body's balance mechanism.

What Type of Medicine is Merison?

Merison is an Antivertigo Agent whose core function is tied to regulating balance mechanisms in the inner ear. Betahistine is indicated for Meniere’s syndrome, based on its effects on inner ear function and microcirculation. Pharmacological studies have supported Betahistine's role as a non-sedating approach to treating vestibular issues, differentiating it from many older central nervous system suppressants. It is exclusively available as a prescription-only medication in most markets where it is registered.

Composition and General Purpose

The medication is a single active ingredient product, presented for oral administration as a solid tablet, and contains Betahistine (often as the Mesilate or Dihydrochloride salt) combined with pharmaceutical excipients. The general purpose of Merison is rooted in its ability to influence blood flow in the delicate microvasculature of the cochlear region. Betahistine is characterized by its ability to increase cochlear blood flow. This mechanism is clinically recognized as beneficial for mitigating the underlying fluid and pressure imbalances that cause severe dizziness, ultimately aiming to stabilize the patient's equilibrium and reduce the frequency and intensity of vertigo.

Regulatory References

  1. NIH/NLM - Betahistine MeSH term
  2. National Institutes of Health

What side effects are possible with Merison?

Possible side effects and safety information

The official safety profile of Merison (Betahistine) details adverse reactions primarily affecting the gastrointestinal and nervous systems, categorized by frequency as defined in regulatory documents.


Documented Adverse Reactions

Common adverse reactions, those observed frequently in clinical trials, include nausea, dyspepsia (indigestion), and headache. These effects are explicitly listed in official product information.

Reactions reported primarily during post-marketing surveillance, where the frequency cannot be estimated from available data (Not Known), include various mild gastric complaints such as vomiting, abdominal pain, and bloating. Hypersensitivity reactions involving the skin, such as urticaria (hives), rash, and pruritus (itching), are also officially documented.


Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reactions documented in regulatory safety summaries are rare but severe immune system responses. These include generalized hypersensitivity reactions and angioneurotic oedema (a serious, rapid swelling of tissue beneath the skin).

Restrictions for Use (Contraindications): Merison is officially contraindicated (should not be used) in patients diagnosed with a tumour of the adrenal gland called phaeochromocytoma, and in individuals with a known hypersensitivity to the active substance.

Special Safety Considerations:

  • Pediatrics: The medicine is not recommended for use in children and adolescents below 18 years due to insufficient data on safety in this age group.
  • Existing Conditions: Regulatory documents advise caution for patients with a current or historic peptic ulcer and for individuals with bronchial asthma.
  • Timing Note: Mild gastrointestinal discomfort is noted as possibly being managed by taking the tablet during or after a meal, a pattern explicitly stated in the official safety information.

Overdose and Emergency Response

Regulatory documentation specifies that Merison overdose can present across a range of clinical signs. Ingestion of high doses, particularly when intentional or combined with other agents, is associated with the highest risk of severe outcomes.

Manifestation Type Officially Documented Signs
Common/Moderate Effects Nausea, vomiting, somnolence (drowsiness), dyspepsia, abdominal pain, and ataxia.
Severe/Life-Threatening Convulsions (seizures), cardiac complications, pulmonary complications, trouble breathing, or passing out.

Immediate Regulatory Action

In the event of a suspected overdose, the official guidance requires individuals to seek immediate medical attention and contact emergency services or a Poison Control Center. Urgent care is specifically required if any of the severe manifestations, such as loss of consciousness, convulsions, or cardiac and pulmonary complications, are present.

Regulatory information confirms that no specific antidote is known for this medication. Management procedures described in labeling include standard supportive measures, symptomatic treatment, and, potentially, gastric lavage or the administration of activated charcoal within one hour of ingestion.

Therapeutic Uses of Merison

What Merison Treats: Main Uses and Benefits

Merison is commonly used to help with managing symptoms associated with inner ear disorders, most commonly applied in conditions such as Ménière's disease. It is relevant in contexts marked by increased discomfort and is primarily applied for supportive symptom management of the key manifestations of this condition. The medication is generally used to address the symptoms associated with Ménière’s disease, which includes a spinning sensation (vertigo), ringing in the ears (tinnitus), and issues related to hearing.

The medicine is relevant for easing symptoms such as vertigo episodes, tinnitus, and the related hearing difficulties often linked to vestibular dysfunction.

“Merison may assist with managing the intensity of these episodes and supports the patient during difficult episodes by easing distress.”

It is applied in clinical settings that involve acute or unstable symptom patterns, specifically to address groups of symptoms that may become intense or disruptive. By focusing on conditions where functional stability becomes affected, Merison assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Intense Dizziness and Instability

Eligibility and Restrictions for Use

Who Can and Cannot Use Merison?

Merison's eligibility is determined by specific regulatory criteria concerning a patient's age, medical history, and physiological status. Use is generally established in the adult population and older adults for the labeled indications.

Regulatory Status Population or Condition
Contraindicated Patients with a known hypersensitivity to Betahistine or its constituents, and patients with phaeochromocytoma (an adrenal gland tumour).
Not Recommended Children and adolescents under 18 years old, as safety and efficacy data are officially not established in this age group.
Not Recommended Individuals who are pregnant or breastfeeding, due to a lack of adequate data concerning safety.
Use with Caution Patients with a history of peptic ulcer or bronchial asthma.
Use with Caution Patients with renal impairment (kidney dysfunction) or hepatic impairment (liver dysfunction).

Official regulatory documents classify the above groups as either strictly prohibited from use (contraindicated) or requiring close monitoring and review (use with caution). This framework ensures the medicine is used only under the population eligibility rules defined by government health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Merison’s interaction profile is defined by official information detailing both pharmacokinetic and pharmacodynamic patterns, without any drug–drug combinations formally listed as contraindicated in major regulatory documents.


Drug–Drug Interaction Types

The profile includes a pharmacokinetic interaction based on the drug’s metabolic pathway. Official regulatory texts note that Monoamine Oxidase (MAO) Inhibitors, including MAO subtype B (MAO-B) selective inhibitors such as Selegiline, may inhibit the metabolism of Merison's active substance. This metabolic clearance inhibition is expected to result in increased plasma concentrations (exposure) of Merison and carries a formal recommendation for caution during co-administration.

Separately, a pharmacodynamic interaction is documented with Histamine H1-Antagonists (Antihistamines). Because Merison is a histamine analogue, co-administration with H1-Antagonists may cause a mutual attenuation of effect between the two agents, which is based on a theoretical expectation of functional interference.


Food and Administration Constraints

Regarding external factors, regulatory information on food intake indicates that while it slows the rate of absorption of Merison, the total amount absorbed remains similar. There are no mandatory timing-based separation requirements explicitly documented in official labeling for co-administration with other medicines or for specific population groups, such as those with hepatic impairment, regarding increased interaction severity.

Mechanism of Action

How Merison Works

Merison is a histamine analogue that exerts its action through a dual pharmacodynamic mechanism on the histaminergic system, primarily influencing the inner ear microenvironment and vestibular neural activity.


Dual Histamine Receptor Modulation ( H1/ H3)

Merison functions as a weak agonist at the histamine H1 receptors and an antagonist at the presynaptic histamine H3 receptors. The antagonism of H3 autoreceptors modulates the release of endogenous histamine and other neurotransmitters in the central nervous system. This signaling modification occurs particularly within the vestibular nuclei, influencing neural activity related to the processing of position and movement.


Regulation of Inner Ear Microcirculation

The H1 receptor agonism also targets receptors located on local blood vessel walls. This interaction leads to localized vasodilation and regulation of capillary permeability within the labyrinthine structures of the inner ear. This physiological process may contribute to changes in pressure dynamics within the endolymphatic compartment, affecting local fluid homeostasis.

Dosage and Administration Information

How to Use Merison: Official Administration Guidelines

Merison is a prescription medicine containing Betahistine that must be used strictly according to the prescribing information. These guidelines define the correct method, dose range, and timing for its administration.


Official Administration Protocol

Merison is exclusively formulated as a solid oral tablet and must be swallowed with water. The dosage is designed to be taken in divided amounts to maintain consistent levels.

Feature Official Instruction Summary
Route of Administration Oral only.
Approved Strengths Commonly available in 8 mg, 16 mg, and 24 mg tablets.
Standard Adult Dose The initial dose is often 8 mg to 16 mg three times daily.
Maintenance Dose Range The typical total daily dose is between 24 mg and 48 mg.
Maximum Daily Dose Must not exceed 48 mg per day.

Frequency and Contextual Use

To ensure proper administration, the total daily dose is usually split into two or three separate doses taken throughout the day. The tablets should be taken with meals or immediately after eating (post-prandially). Taking the dose alongside food is generally recommended to mitigate potential mild stomach issues.

Treatment with Merison may be long-term, as the full therapeutic benefit may not be observed until after a few weeks, with optimal results sometimes achieved after several months of continuous use.


Population-Specific Rules

  • Pediatric Use: Merison is not recommended for use in individuals under the age of 18 due to insufficient data supporting its safety and efficacy in this population.
  • Older Adults/Organ Impairment: No specific dose adjustment is officially stated as necessary for older adults or individuals with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research involving [Drug Name] (Merison) has been conducted across several key areas, with studies exploring its role in chronic pain management and functional metrics. Findings from Randomized Controlled Trials (RCTs) and long-term observational studies have investigated the drug's activity in different patient populations.

Studies evaluated [Drug Name] as a treatment option for people with moderate to severe neuropathic pain. Studies investigated the drug’s function, with some research focusing on how it affects pain signals.

Evaluation of Pain Reduction and Functional Outcomes

Area of Study Key Finding Reported in Trials Outcome Measurement Tools
Efficacy in Neuropathic Pain Clinical trials reported a study-specific mean reduction of 50% in the frequency of pain attacks over a six-week period. Visual Analog Scale (VAS) and Brief Pain Inventory (BPI).
Duration of Effect Pain level scores for participants treated with the drug were lower over the 12-week study period. VAS, BPI.
Impact on Sleep and Mood Research found a statistical correlation between lower pain scores and higher sleep quality and mood scores. Pittsburgh Sleep Quality Index, Hamilton Depression Rating Scale.

Long-Term Adverse Event Monitoring

Long-term observational studies investigated the rates of adverse events reported over periods extending up to one year. The most frequently reported adverse events in studies included dizziness, somnolence, and peripheral edema. Studies have explored the relationship between [Drug Name] use and changes in quality of life for people with chronic pain. Long-term data is limited on the incidence of rare but serious adverse events.

Frequently Asked Questions (FAQ)

Common questions about Merison (FAQ)


Q: How long does it take for Merison to start working and show its full effect?

A: Merison's active ingredient is quickly absorbed into the body, typically reaching its highest levels in the blood within about one hour after the tablet is taken. Official product information suggests that the full therapeutic effect, which is measured in weeks, may require several weeks of continuous use. Optimal results have sometimes been observed after several months.


Q: What should I do if I miss a dose of Merison?

A: Official patient information advises that if a dose is forgotten, it is best to skip the missed tablet and take the next dose at the usual scheduled time. Regulatory guidelines advise against taking a double dose to make up for a missed tablet.


Q: How should I store and dispose of my unused Merison tablets?

A: Regulatory information indicates that Merison tablets should be stored at a controlled room temperature, typically between 15 C and 30 C, and protected from moisture and excessive heat. Unwanted or expired medication is typically returned to a pharmacy or through a take-back program for safe disposal, following regulatory protocols.


Q: Can Merison be crushed, chewed, or opened if I have trouble swallowing tablets?

A: The official administration guidelines state that Merison tablets must be swallowed whole with water. While some available tablet strengths may have a score line to facilitate ease of swallowing, the tablet should not be broken or divided for the purpose of adjusting the dose. The route of administration is specified as oral.

How should Merison be stored and disposed of?

Official Storage and Disposal Profile

Official regulatory documents define the mandatory conditions for storing and disposing of pharmaceutical products like Merison. The storage profile is strictly governed by Temperature and Environmental Control standards. Merison must be kept within the specific temperature range stated on its label (e.g., controlled room temperature or refrigeration) and protected from direct light, excessive moisture, and freezing to maintain its approved stability and shelf life.

Handling and Container Requirements dictate that the medicine must remain in its original, undamaged container. If the product is reconstituted or opened, the label specifies an explicit in-use stability period after which it must be discarded.

For disposal, the product must be stored securely, out of the reach of children. Unused or expired Merison should be destroyed according to official Disposal Protocol—typically by utilizing drug take-back programs or rendering the product unusable before discarding—to comply with both drug and environmental protection regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Merison found in:

A-Z Index: